Moreover, the types of BRCA1/2 mutations also differ substantially from foreign data (41, 44), likely contributing to discrepancies in breast and ovarian cancer risk for BRCA1/2 carriers in China. This evidence concerns the gene BRCA1 and ovarian carcinoma.